Part 1 MAD examine will likely be performed to judge the security, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) traits of ID110521156 following repeated administration and stepwise enhance in dose.
Beforehand, Yunovia not solely confirmed the drug’s effectiveness associated to insulin secretion and blood glucose management, but in addition, its superior tolerability in comparison with different medicine in the identical class by way of preclinical efficacy and toxicity evaluations within the just lately accomplished Part 1 SAD examine.
ID110521156 is a GLP-1 (glucagon-like peptide-1) receptor agonist that performs the identical position because the GLP-1 hormone which is concerned within the synthesis and secretion of insulin within the physique, discount of blood glucose degree, regulation of gastrointestinal tract actions, and urge for food suppression.
Since ID110521156 is a small molecule compound, the Firm’s technique is to develop it as an orally administrable drug for diabetes and weight problems with differentiated attributes similar to superior manufacturability and ease of use in comparison with peptide injections, the present customary of care.
A Yunovia consultant emphasised, “ID110521156 is the one small molecule based mostly new drug within the medical stage amongst all GLP-1 receptor agonists in
The Firm consultant additional acknowledged, “We had been speaking with potential associate firms from the early growth stage the place their suggestions from the angle of the wants of the ‘GLP-1 market’, had been mirrored within the designing of the SAD and MAD research” Primarily based on our persevering with dialogue with them, we’ll proceed with additional growth of ID110521156 and, pursue international out-licensing.
About ID110521156
ID110521156 is an orally obtainable small molecule agonist of the GLP-1 receptor. Yunovia accomplished its Part I SAD, together with meals impact examine, in
About Yunovia
Yunovia was established in 2023 as a split-off from Ildong pharmaceutical to launch the total potential worth of world, modern drug pipeline and to maximise the R&D productiveness for accelerated drug growth. Yunovia’s R&D pipeline contains greater than 20 modern packages at numerous growth levels for numerous therapeutic areas. With its small molecule R&D experience and pipeline, together with 3+ medical packages, Yunovia will try to develop as a number one innovator for all times altering therapeutics. For extra data, please go to https://www.yunovia.com/eng/foremost/.
CONTACT: